Larry J Dumont

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3216474/publications.pdf

Version: 2024-02-01

96 papers 3,184 citations

33 h-index 53 g-index

100 all docs

100 docs citations

100 times ranked 2953 citing authors

#	Article	IF	CITATIONS
1	A Multicenter, Prospective, Observational, Cohort-Controlled Study of Clinical Outcomes Following Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Therapy in Hospitalized Patients With COVID-19. Clinical Infectious Diseases, 2022, 75, e466-e472.	5.8	9
2	Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support. Annals of Thoracic Surgery, 2022, 113, 1026-1035.	1.3	9
3	Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications. Emerging Infectious Diseases, 2022, 28, 672-683.	4.3	49
4	Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation. PLoS Pathogens, 2022, 18, e1009925.	4.7	8
5	Cryopreservation of rare pediatric red blood cells for support following bone marrow transplant. Transfusion, 2022, 62, 954-960.	1.6	5
6	Commentary on the 1976 <i>Transfusion</i> paper by Aster, Becker, and Filip. Transfusion, 2022, 62, 942-947.	1.6	0
7	Evaluation of amotosalen and <scp>UVA pathogen</scp> â€reduced apheresis platelets after 7â€day storage. Transfusion, 2022, 62, 1619-1629.	1.6	3
8	Blood donor obesity is associated with changes in red blood cell metabolism and susceptibility to hemolysis in cold storage and in response to osmotic and oxidative stress. Transfusion, 2021, 61, 435-448.	1.6	29
9	Selecting COVID â€19 convalescent plasma for neutralizing antibody potency using a highâ€capacity SARSâ€CoV â€2 antibody assay. Transfusion, 2021, 61, 1160-1170.	1.6	18
10	Blood donor exposome and impact of common drugs on red blood cell metabolism. JCI Insight, 2021, 6,	5.0	39
11	Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray. Scientific Reports, 2021, 11, 7554.	3.3	11
12	Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma. Journal of Clinical Immunology, 2021, 41, 1169-1171.	3.8	53
13	<scp>SARSâ€CoV</scp> â€2 antibody persistence in <scp>COVID</scp> â€19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. Transfusion, 2021, 61, 2677-2687.	1.6	46
14	The evolution of <scp>COVID</scp> â€19 vaccination within a <scp>US</scp> blood center. Transfusion, 2021, 61, 2528-2529.	1.6	2
15	Progression and Predictors of SARS-CoV-2 Antibody Seroreactivity In US Blood Donors. Transfusion Medicine Reviews, 2021, 35, 8-15.	2.0	7
16	Early Convalescent Plasma for High-Risk Outpatients with Covid-19. New England Journal of Medicine, 2021, 385, 1951-1960.	27.0	177
17	Toxic masculinity in red blood cell units? Testosterone therapy in blood donors revisited. Transfusion, 2021, 61, 3174-3180.	1.6	2
18	Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Science Translational Medicine, 2021, 13, eabh2624.	12.4	155

#	Article	IF	CITATIONS
19	Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Medicine, 2021, 18, e1003872.	8.4	43
20	Frozen Platelets—Development and Future Directions. Transfusion Medicine Reviews, 2020, 34, 286-293.	2.0	15
21	Nicotine exposure increases markers of oxidant stress in stored red blood cells from healthy donor volunteers. Transfusion, 2020, 60, 1160-1174.	1.6	33
22	Retrospective cohort studies of repeat donors reveal donorâ€dependent variability in the recovery of transfused platelets. Transfusion, 2020, 60, 1837-1845.	1.6	1
23	The prevalence and demographic determinants of blood donors receiving testosterone replacement therapy at a large USA blood service organization. Transfusion, 2020, 60, 947-954.	1.6	5
24	Impact of taurine on red blood cell metabolism and implications for blood storage. Transfusion, 2020, 60, 1212-1226.	1.6	30
25	Platelets: Frozen and Freeze-Dried Current Products in Development and Regulatory Licensing Challenges., 2020,, 163-184.		0
26	Frozen platelets. Transfusion and Apheresis Science, 2019, 58, 23-29.	1.0	15
27	Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems. Transfusion, 2018, 58, 943-950.	1.6	7
28	A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers. Transfusion Medicine Reviews, 2018, 32, 102-110.	2.0	22
29	Comparison between manufacturing sites shows differential adhesion, activation, and GPIbα expression of cryopreserved platelets. Transfusion, 2018, 58, 2645-2656.	1.6	29
30	Methylation of protein aspartates and deamidated asparagines as a function of blood bank storage and oxidative stress in human red blood cells. Transfusion, 2018, 58, 2978-2991.	1.6	71
31	Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia. Transfusion, 2018, 58, 2129-2138.	1.6	53
32	Red blood cell metabolic responses to refrigerated storage, rejuvenation, and frozen storage. Transfusion, 2017, 57, 1019-1030.	1.6	52
33	In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets. Transfusion, 2016, 56, 580-586.	1.6	42
34	How do we implement Day 6 and Day 7 platelets at a hospitalâ€based transfusion service?. Transfusion, 2016, 56, 1262-1266.	1.6	21
35	CO ₂ â€dependent metabolic modulation in red blood cells stored under anaerobic conditions. Transfusion, 2016, 56, 392-403.	1.6	50
36	Metabolic pathways that correlate with post-transfusion circulation of stored murine red blood cells. Haematologica, 2016, 101, 578-586.	3.5	69

#	Article	IF	CITATIONS
37	Interference of New Drugs with Compatibility Testing for Blood Transfusion. New England Journal of Medicine, 2016, 375, 295-296.	27.0	28
38	International validation of a dithiothreitol (DTT)â€based method to resolve the daratumumab interference with blood compatibility testing. Transfusion, 2016, 56, 2964-2972.	1.6	76
39	Metabolomics in transfusion medicine. Transfusion, 2016, 56, 980-993.	1.6	104
40	Treatment of Bleeding in Severely Thrombocytopenic Patients with Transfusion of Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP) Is Safe - Report of a Phase 1 Dose Escalation Safety Trial. Blood, 2016, 128, 1030-1030.	1.4	5
41	The In Vivo Recovery/Survivaland Pharmacokinetic Properties of Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes. Blood, 2016, 128, 2629-2629.	1.4	2
42	Deterioration of red blood cell mechanical properties is reduced in anaerobic storage. Blood Transfusion, 2016, 14, 80-8.	0.4	29
43	The bioequivalence of frozen plasma prepared from whole blood held overnight at room temperature compared to fresh-frozen plasma prepared within eight hours of collection. Transfusion, 2015, 55, 476-484.	1.6	11
44	Additive solutionâ€7 reduces the red blood cell cold storage lesion. Transfusion, 2015, 55, 491-498.	1.6	67
45	Overnight, room temperature hold of whole blood followed by 42-day storage of red blood cells in additive solution-7. Transfusion, 2015, 55, 485-490.	1.6	16
46	Red blood cell storage in additive solutionâ€7 preserves energy and redox metabolism: a metabolomics approach. Transfusion, 2015, 55, 2955-2966.	1.6	63
47	International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing. Blood, 2015, 126, 3567-3567.	1.4	2
48	Cryopreserved platelets: frozen in a logjam?. Transfusion, 2014, 54, 1907-1910.	1.6	19
49	Novel platelet storage conditions. Current Opinion in Hematology, 2014, 21, 491-496.	2.5	26
50	Metabolomics of ADSOL (AS-1) Red Blood Cell Storage. Transfusion Medicine Reviews, 2014, 28, 41-55.	2.0	83
51	A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide–frozen autologous platelets in healthy volunteers. Transfusion, 2013, 53, 128-137.	1.6	75
52	FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma. Journal of Hematopathology, $2013, 6, 11-18$.	0.4	20
53	In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion, 2013, 53, 972-980.	1.6	25
54	A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. Transfusion, 2013, 53, 1328-1334.	1.6	5

#	Article	IF	CITATIONS
55	Routine bacterial screening of apheresis platelets on <scp>D</scp> ay 4 using a rapid test: a 4â€year singleâ€center experience. Transfusion, 2013, 53, 2307-2313.	1.6	25
56	Correlation Between Red Blood Cell Survival and Cytochrome P450 1A2 Enzyme Activity. Blood, 2013, 122, 3658-3658.	1.4	4
57	ABO incompatible platelets. Current Opinion in Hematology, 2012, 19, 475-479.	2.5	49
58	Retrograde patient blood flow and rouleaux preventing red blood cell transfusion. Transfusion, 2012, 52, 2284-2284.	1.6	0
59	Successful use of citrate anticoagulant with heparin bolus for excessive clotting during extracorporeal photopheresis. Transfusion, 2012, 52, 2494-2495.	1.6	3
60	Exploratory in vitro study of red blood cell storage containers formulated with an alternative plasticizer. Transfusion, 2012, 52, 1439-1445.	1.6	39
61	Red blood cell storage in SAGM and AS3: a comparison through the membrane two-dimensional electrophoresis proteome. Blood Transfusion, 2012, 10 Suppl 2, s46-54.	0.4	35
62	A Genetic Basis for Donor Variation in Generation of Prostaglandins and Leukotrienes in Stored RBCs Using a Mouse Model. Blood, 2012, 120, 844-844.	1.4	0
63	Bacterial growth kinetics in ACDâ€A apheresis platelets: comparison of plasma and PAS III storage. Transfusion, 2011, 51, 1079-1085.	1.6	22
64	A randomized controlled trial comparing autologous radiolabeled in vivo platelet (PLT) recoveries and survivals of 7â€dayâ€stored PLTâ€rich plasma and buffy coat PLTs from the same subjects. Transfusion, 2011, 51, 1241-1248.	1.6	21
65	Rejuvenation capacity of red blood cells in additive solutions over longâ€ŧerm storage. Transfusion, 2011, 51, 1574-1579.	1.6	40
66	Validation of a microbial detection system for use with ACDâ€A platelets with PAS III platelet additive solution. Transfusion, 2011, 51, 2219-2227.	1.6	8
67	Stored red blood cell viability is maintained after treatment with a secondâ€generation Sâ€303 pathogen inactivation process. Transfusion, 2011, 51, 2367-2376.	1.6	33
68	BLOOD COMPONENTS: Screening of singleâ€donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion, 2010, 50, 589-599.	1.6	121
69	Practices associated with ABOâ€incompatible platelet transfusions: a BEST Collaborative international survey. Transfusion, 2010, 50, 1743-1748.	1.6	37
70	A systematic assessment of the quality of reporting for platelet transfusion studies. Transfusion, 2010, 50, 2135-2144.	1.6	19
71	Quality Improvement by Standardization of Procurement and Processing of Thyroid Fine-Needle Aspirates in the Absence of On-site Cytological Evaluation. Thyroid, 2009, 19, 1049-1052.	4.5	26
72	Anaerobic storage of red blood cells in a novel additive solution improves in vivo recovery. Transfusion, 2009, 49, 458-464.	1.6	51

#	Article	IF	CITATIONS
73	The impact of discontinuation of 7â€day storage of apheresis platelets (PASSPORT) on recipient safety: an illustration of the need for proper risk assessments. Transfusion, 2009, 49, 903-912.	1.6	30
74	Hematopoietic stem cell transplantation: is ABO "A match made in heaven�. Transfusion, 2009, 49, 612-614.	1.6	2
75	Exploratory in Vitro Study of Red Blood Cell Storage Container with An Alternative Plasticizer Blood, 2009, 114, 3149-3149.	1.4	O
76	Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials. Transfusion, 2008, 48, 1053-1060.	1.6	213
77	Comparing the efficacy and safety of apheresis and whole blood–derived platelet transfusions: a systematic review. Transfusion, 2008, 48, 1447-1458.	1.6	71
78	The effects of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells. Transfusion, 2008, 48, 2096-2105.	1.6	50
79	Shake, rattle, and roll . . preventing platelets from turning into Golden Oldies. Transfusion, 2008, 48, 2487-2489.	'1.6	2
80	The above letter was sent to Drsâ€∫AuBuchon and Dumont; they offered the following reply Transfusion, 2007, 47, 947-947.	1.6	0
81	Interruption of agitation of platelet concentrates: a multicenter in vitro study by the BEST Collaborative on the effects of shipping platelets. Transfusion, 2007, 47, 1666-1673.	1.6	39
82	Automated collection of double red blood cell units with a variable-volume separation chamber. Transfusion, 2007, 48, 071003012013004-???.	1.6	2
83	Recovery of Donor Peripheral Blood Platelet Count Following Platelet Apheresis Blood, 2007, 110, 2892-2892.	1.4	O
84	A flow cytometric method for detection and enumeration of low-level, residual red blood cells in platelets and mononuclear cell products. Transfusion, 2006, 46, 966-972.	1.6	15
85	In vitro pH effects on in vivo recovery and survival of platelets: an analysis by the BEST Collaborative. Transfusion, 2006, 46, 1300-1305.	1.6	55
86	Random Healthy Donor Sera Show Varying Effectiveness in Hemolyzing ABO Incompatible Red Blood Cells Blood, 2006, 108, 958-958.	1.4	1
87	Comparison of computerized formulae for determination of platelet recovery and survival. Transfusion, 2005, 45, 1237-1239.	1.6	4
88	Seven-day storage of apheresis platelets: report of an in vitro study. Transfusion, 2003, 43, 143-150.	1.6	50
89	Sevenâ \in day storage of singleâ \in donor platelets: recovery and survival in an autologous transfusionâ \in f study. Transfusion, 2002, 42, 847-854.	1.6	138
90	Autologous transfusion recovery of WBC-reduced high-concentration platelet concentrates. Transfusion, 2002, 42, 1333-1339.	1.6	9

#	Article	IF	CITATIONS
91	The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood, 2001, 97, 3640-3647.	1.4	53
92	Detecting failed WBC-reduction processes:computer simulations of intermittent and continuous process failure. Transfusion, 2000, 40, 1427-1433.	1.6	11
93	Ex Vivo Factors Affecting Contact Phase Activation in Negatively Charged Medical Devices. Blood, 1999, 93, 2129-2131.	1.4	1
94	Platelet surface P-selectin measurements in platelet preparations: An international collaborative study. Transfusion Medicine Reviews, 1999, 13, 31-42.	2.0	56
95	Statistical Process Validation of Leucoreduced Blood Components. Transfusion Science, 1998, 19, 35-37.	0.6	2
96	Applications of Cellular Radiolabeling in Transfusion Medicine., 0,, 298-317.		2